Kymera Therapeutics, Inc.

KYMR

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$119.77

−$1.70 · -1.40%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

39/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Expensive

Momentum

Gaining

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Nello Mainolfi
Listed since: Aug 21, 2020
Employees: 273

Market position

Volume: 503.43K; 0.68× average
Average volume: 742.33K; Average daily volume
Market cap: 9.85B USD
Beta: 1.95; Market reference 1

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score: 41.21
Piotroski F-score: 4 of 9

Earnings

Latest fiscal-year EPS: -3.69; FY2025
Latest fiscal-year revenue: 39.2M USD; FY2025 · -16.72% year over year
Next fiscal-year EPS consensus: -3.81; FY2026 · 16 analysts
Next fiscal-year revenue consensus: 106.15M USD; FY2026 · 18 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$129.64

8.21% upside

Past 12 months12-month forecast

Price history unavailable

High $155Average $129.64Low $97.00

Rating distribution

27 ratings

Strong buy00%

Buy2385%

Hold415%

Sell00%

Strong sell00%

Recent analyst actions

12 institutions

Canaccord GenuitymaintainBuyJun 26, 2026

KYMR news

zacks.comAug 6, 2026

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

Read source

seekingalpha.comAug 5, 2026

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Read source

marketbeat.comAug 5, 2026

Kymera Therapeutics Q2 Earnings Call Highlights

Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and…

Read source

zacks.comAug 5, 2026

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.

Read source

globenewswire.comAug 5, 2026

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621…

Read source

247wallst.comJul 30, 2026

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy…

Read source